AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06174909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple Antibiotic paste
Description: After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
Study NCT04942990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calisthenic exercises
Description: these exercises are a kind of exercise for increasing cardiovascular endurance
Study NCT05173701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
Study NCT05173701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
Study NCT05622214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Else nutrition formula
Description: Plant based nutrition from almond and buckwheat
Study NCT05897697 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Structured interview
Study NCT05856565 — intervention group
Intervention type: OTHER
Intervention: Photo
Description: Photography intake
Study NCT05058846 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood, tissue, and saliva collection
Study NCT05058846 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Undergo MRCP
Study NCT05058846 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05905068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RN0191 INJECTION
Description: a sterile solution in each bottle for subcutaneous (SC) injection
Study NCT04075240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG and acetylsalicylic acid 81 mg
Description: Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
Study NCT04075240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid 81 mg
Description: Starting post op, aspirin for 9 days for TKA and 30 days for THA
Study NCT05058846 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound
Description: Undergo endoscopic ultrasound
Study NCT05058846 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
Study NCT05529004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Capsule pregapalin
Description: oral cap of pregapalin has been administration to patient before surgery to prvent PONV
Study NCT05529004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laparoscope device
Description: general anesthesia with complete relaxation under laparoscopic cholecystectomy
Study NCT05117177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inupadenant
Description: Oral administration
Study NCT06325956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Take metformin for six months.
Study NCT04741828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Description: Typhoid Conjugate Vaccine
Study NCT05004129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
Study NCT04787562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose
Study NCT04787562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose
Study NCT06460649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive relaxation techniques
Description: Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
Study NCT06460649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation techniques
Description: Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
Study NCT06460649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benson relaxation techniques
Description: Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
Study NCT04789174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solriamfetol
Description: Solriamfetol 75 mg/d Solriamfetol 150 mg/d
Study NCT04789174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04912765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Dendritic Cell Vaccine
Description: 10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
Study NCT04912765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
Study NCT06041438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862
Study NCT06041438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: itraconazole
Study NCT04108858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT04108858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT04108858 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given IV
Study NCT04108858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT04108858 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study NCT05211726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Added Sugar Diet
Description: Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)
Study NCT05211726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Added Sugar Diet
Description: Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
Study NCT05534230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Solution
Description: Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
Study NCT06329024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06329024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT05534230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
Study NCT04828174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-TRBC1 CAR-T cell therapy
Description: TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
Study NCT06462248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUCART19
Description: anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
Study NCT06329024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study NCT06011707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPT-IN
Description: Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
Study NCT06011707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational control
Description: This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
Study NCT06257251 — intervention group
Intervention type: OTHER
Intervention: Histological slides digitization
Description: Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
Study NCT05411341 — intervention group
Intervention type: DEVICE
Intervention: Argos (Alcon Laboratories, Inc.)
Description: An ocular biometry examination will be performed on the affected eyes using the Argos device.
Study NCT05411341 — intervention group
Intervention type: DEVICE
Intervention: IOLMaster 500 (Carl Zeiss Meditec AG)
Description: An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
Study NCT01024257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: beta-irradiation
Study NCT01024257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autograft
Study NCT06540989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Description: Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
Study NCT06540989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deferred treatment
Description: This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
Study NCT05293678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (IV)
Description: Administered in single intravenous (IV) dose
Study NCT05352555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated vertigo repositioning chair
Description: Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest.
Study NCT05352555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canalith Reposition Maneuver
Description: Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest.
Study NCT05990556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional procedure to block bilateral meningeal blood supply
Description: The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging.
Study NCT05293678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (IV)
Description: Administered in single IV dose
Study NCT05165420 — intervention group
Intervention type: OTHER
Intervention: Cosmetic product
Description: RV4941A is a face cream product
Study NCT05293678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (SC)
Description: Administered in single subcutaneous (SC) dose
Study NCT06034977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADI-PEG20
Description: Lenvatinib + ADI-PEG20 combination treatment.
Study NCT06034977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Lenvatinib + ADI-PEG20 combination treatment.
Study NCT05390710 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LAE005 + Afuresertib + Nab-Paclitaxel
Description: LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
Study NCT05293678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (SC)
Description: Administered in single SC dose
Study NCT06229054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
Study NCT06229054 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: local anesthesic which works through blocking sodium channels
Study NCT06229054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: local anesthesic which works through blocking sodium channels
Study NCT05095415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Pre-operative Consult
Description: Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
Study NCT05095415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Pre-Operative Education
Description: Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
Study NCT06213181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
Study NCT05728281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recommended time after hysterectomy
Description: Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
Study NCT05265507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
Study NCT05265507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
Study NCT06289543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative carbohydrate solution
Description: water and solution will be given to patients to drink 2 hours before the operation
Study NCT04874129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YYC506-T and YYC506-A (phase 1)
Description: Comparator
Study NCT04874129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YYC506 (phase 1)
Description: Test
Study NCT04874129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YYC506-T and YYC506-A (phase 2)
Description: Comparator
Study NCT04874129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YYC506 (phase 2)
Description: Test